{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:22:46Z","timestamp":1787952166788,"version":"build-2784847793"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.blre.2026.101413","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:37:32Z","timestamp":1781969852000},"page":"101413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["MRD in multiple myeloma: Moving from \u201cminimal\u201d to \u201cmeasurable\u201d"],"prefix":"10.1016","volume":"77","author":[{"given":"Raffaella Cassano","family":"Cassano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimaz","family":"Afrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Portuguese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laahn","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silviya","family":"Meletath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Serviddio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.blre.2026.101413_bb0005","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/blood.V70.4.1073.1073","article-title":"Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease","volume":"70","author":"Martens","year":"1987","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2026.101413_bb0010","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101413_bb0015","series-title":"Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement 2024","author":"Food and Drug Administration","year":"2024"},{"key":"10.1016\/j.blre.2026.101413_bb0025","series-title":"CARVYKTI\u00ae significantly improved minimal residual disease negativity compared to standard of Care for Patients with relapsed or refractory multiple myeloma","author":"Legend Biotech","year":"2024"},{"key":"10.1016\/j.blre.2026.101413_bb0030","series-title":"Blincyto - opinion on variation to marketing authorisation","author":"European Medicines Agency","year":"2024"},{"key":"10.1016\/j.blre.2026.101413_bb0035","series-title":"Ten years of BLINCYTO\u00ae (blinatumomab): Celebrating the history, impact and future","author":"Amgen Inc.","year":"2024"},{"issue":"5","key":"10.1016\/j.blre.2026.101413_bb0040","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood.V99.5.1853","article-title":"Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome","volume":"99","author":"San Miguel","year":"2002","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2026.101413_bb0045","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2026.101413_bb0050","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.blre.2026.101413_bb0055","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101413_bb0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2026.101413_bb0065","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2026.101413_bb0070","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/j.clml.2023.02.005","article-title":"Association of minimal residual disease negativity rates with progression free survival in frontline therapy trials for newly diagnosed multiple myeloma: a meta-analysis","volume":"23","author":"Ficek","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.blre.2026.101413_bb0075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ajh.27582","article-title":"Evaluating minimal residual disease negativity as a surrogate endpoint for treatment efficacy in multiple myeloma: a meta-analysis of randomized controlled trials","volume":"100","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.blre.2026.101413_bb0080","first-page":"2049","article-title":"Role of minimal residual disease assessment in multiple myeloma","volume":"109","author":"Szalat","year":"2024","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2026.101413_bb0085","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1080\/10428194.2017.1386304","article-title":"Minimal residual disease analysis in myeloma - when, why and where","volume":"59","author":"Yanamandra","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.blre.2026.101413_bb0090","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: bringing the bench to the bedside","volume":"12","author":"Mailankody","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2026.101413_bb0095","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2026.101413_bb0100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2026.101413_bb0105","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2026.101413_bb0110","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101413_bb0115","doi-asserted-by":"crossref","first-page":"100732","DOI":"10.1016\/j.blre.2020.100732","article-title":"Defining the undetectable: the current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity","volume":"46","author":"Diamond","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2026.101413_bb0120","first-page":"9699","article-title":"Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives","author":"Romano","year":"2019","journal-title":"Front Oncol"},{"issue":"26","key":"10.1016\/j.blre.2026.101413_bb0125","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2026.101413_bb0130","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/1078-0432.CCR-20-2995","article-title":"Capture rate of V(D)J sequencing for minimal residual disease detection in multiple myeloma","volume":"28","author":"Hultcrantz","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2026.101413_bb0135","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"23","key":"10.1016\/j.blre.2026.101413_bb0140","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/blood.V126.23.191.191","article-title":"Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM\/DFCI 2009 trial","volume":"126","author":"Avet-Loiseau","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2026.101413_bb0145","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2026.101413_bb0150","doi-asserted-by":"crossref","first-page":"102016","DOI":"10.1016\/j.eclinm.2023.102016","article-title":"Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing","volume":"60","author":"Oliva","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.blre.2026.101413_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-071548","article-title":"Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2024","journal-title":"BMJ Open"},{"issue":"27","key":"10.1016\/j.blre.2026.101413_bb0160","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key Hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2026.101413_bb0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"issue":"27","key":"10.1016\/j.blre.2026.101413_bb0170","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.blre.2026.101413_bb0175","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101413_bb0180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.24.00635","article-title":"Minimally invasive assessment of peripheral residual disease during maintenance or observation in transplant-eligible patients with multiple myeloma","volume":"43","author":"Lasa","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2026.101413_bb0185","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.seminoncol.2018.01.009","article-title":"Cell-free DNA as a post-treatment surveillance strategy: current status","volume":"44","author":"Burgener","year":"2017","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2026.101413_bb0190","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2017-03-735639","article-title":"High-throughput sequencing for noninvasive disease detection in hematologic malignancies","volume":"130","author":"Scherer","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101413_bb0195","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.blre.2026.101413_bb0200","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","article-title":"Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma","volume":"9","author":"Manier","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.blre.2026.101413_bb0205","first-page":"102016","article-title":"Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates","volume":"60","author":"Kis","year":"2023","journal-title":"Nat Commun"},{"issue":"21","key":"10.1016\/j.blre.2026.101413_bb0210","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2026.101413_bb0215","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-018-0160-x","article-title":"Molecular signatures of multiple myeloma progression through single cell RNA-Seq","volume":"9","author":"Jang","year":"2019","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.blre.2026.101413_bb0220","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.blre.2026.101413_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.seminhematol.2018.02.008","article-title":"Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease","volume":"55","author":"Thoren","year":"2018","journal-title":"Semin Hematol"},{"issue":"7","key":"10.1016\/j.blre.2026.101413_bb0230","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jmoldx.2020.04.002","article-title":"Mass spectrometry-based method targeting Ig variable regions for assessment of minimal residual disease in multiple myeloma","volume":"22","author":"Martins","year":"2020","journal-title":"J Mol Diagn"},{"issue":"10","key":"10.1016\/j.blre.2026.101413_bb0235","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.blre.2026.101413_bb0240","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.jproteome.7b00890","article-title":"Development of a targeted mass-spectrometry serum assay to quantify M-protein in the presence of therapeutic monoclonal antibodies","volume":"17","author":"Zajec","year":"2018","journal-title":"J Proteome Res"},{"issue":"3","key":"10.1016\/j.blre.2026.101413_bb0245","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1515\/cclm-2023-0781","article-title":"M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator","volume":"62","author":"Wijnands","year":"2024","journal-title":"Clin Chem Lab Med"},{"issue":"24","key":"10.1016\/j.blre.2026.101413_bb0250","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1182\/bloodadvances.2024015685","article-title":"Clinical applications of mass spectrometry in multiple myeloma","volume":"9","author":"Derman","year":"2025","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.blre.2026.101413_bb0255","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1093\/clinchem\/hvab187","article-title":"Multiple myeloma minimal residual disease detection: targeted mass spectrometry in blood vs next-generation sequencing in bone marrow","volume":"67","author":"Langerhorst","year":"2021","journal-title":"Clin Chem"},{"issue":"23","key":"10.1016\/j.blre.2026.101413_bb0260","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood.2024024995","article-title":"Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma","volume":"144","author":"Puig","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2026.101413_bb0265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.blre.2026.101413_bb0270","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood.2024024041","article-title":"Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma","volume":"144","author":"Kubicki","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101413_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101148","article-title":"Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders","volume":"33","author":"Ulaner","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"10.1016\/j.blre.2026.101413_bb0280","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2026.101413_bb0285","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1080\/10428190600647723","article-title":"Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis","volume":"47","author":"Dimopoulos","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.blre.2026.101413_bb0290","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.blre.2026.101413_bb0295","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101413_bb0300","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica"},{"issue":"Supplement_1","key":"10.1016\/j.blre.2026.101413_bb0305","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2019-123143","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101413_bb0310","first-page":"13627","article-title":"Impact of imaging FDG-PET\/CT minimal residual disease assessment on outcomes and matching with bone marrow techniques in newly diagnosed transplant eligible multiple myeloma (MM) patients: results of the phase II randomized Forte trial","author":"Zamagni","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101413_bb0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminhematol.2018.02.009","article-title":"Functional imaging methods for assessment of minimal residual disease in multiple myeloma: current status and novel ImmunoPET based methods","volume":"55","author":"Pandit-Taskar","year":"2018","journal-title":"Semin Hematol"},{"issue":"1115","key":"10.1016\/j.blre.2026.101413_bb0320","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20200312","article-title":"Pictorial review of whole body MRI in myeloma: emphasis on diffusion-weighted imaging","volume":"93","author":"Hameed","year":"2020","journal-title":"Br J Radiol"},{"issue":"9","key":"10.1016\/j.blre.2026.101413_bb0325","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2026.101413_bb0330","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.blre.2026.101413_bb0335","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction","volume":"125","author":"Rawstron","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2026.101413_bb0340","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2026.101413_bb0345","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"de Tute","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2026.101413_bb0350","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101413_bb0355","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-142913","volume":"136","author":"Krishnan","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2026.101413_bb0360","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"issue":"10297","key":"10.1016\/j.blre.2026.101413_bb0365","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.blre.2026.101413_bb0370","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101413_bb0375","first-page":"22S410","author":"Usmani","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"10.1016\/j.blre.2026.101413_bb0380","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with Ciltacabtagene Autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101413_bb0385","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood-2025-258","article-title":"A dual targeting BCMA and CD19 fastcar-t (GC012F\/AZD0120) as first-line therapy for newly diagnosed multiple myeloma","volume":"146","author":"Du","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101413_bb0390","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood-2025-256","article-title":"Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: updated results from iMMagine\u20131","volume":"146","author":"Patel","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101413_bb0395","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2026.101413_bb0400","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1470-2045(25)00653-9","article-title":"Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial","volume":"27","author":"Einsele","year":"2026","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101413_bb0405","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2024-201533","article-title":"Ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SoC) in patients with lenalidomide (Len)-refractory multiple myeloma (MM) after 1-3 lines of therapy: minimal residual disease (MRD) negativity in the phase 3 Cartitude-4 trial","volume":"144","author":"Popat","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2026.101413_bb0410","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.blre.2026.101413_bb0415","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.blre.2026.101413_bb0420","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.7528","article-title":"Efficacy and safety from the phase 1\/2 MonumenTAL-1 study of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma: analyses at an extended median follow-up","volume":"43","author":"Rasche","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2026.101413_bb0425","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101413_bb0430","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood-2025-698","article-title":"Efficacy and safety of talquetamab + teclistamab in patients with relapsed\/refractory multiple myeloma and extramedullary disease: updated phase 2 results from the redirectt-1 study with extended follow-up","volume":"146","author":"Usmani","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2026.101413_bb0435","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2026.101413_bb0440","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2603870","article-title":"Teclistamab in multiple myeloma with one to three previous lines of therapy","author":"Touzeau","year":"2026","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.blre.2026.101413_bb0445","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter?","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101413_bb0450","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.blre.2026.101413_bb0455","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2023022083","article-title":"Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma","volume":"143","author":"Guerrero","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101413_bb0460","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-024-01030-w","article-title":"Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk","volume":"14","author":"Callander","year":"2024","journal-title":"Blood Cancer J"},{"issue":"20","key":"10.1016\/j.blre.2026.101413_bb0465","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1182\/blood.2024027686","article-title":"Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma","volume":"145","author":"Terpos","year":"2025","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2026.101413_bb0470","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101413_bb0475","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2021-146798","article-title":"Ixazomib plus lenalidomide\/dexamethasone (IRd) versus lenalidomide \/dexamethasone (Rd) maintenance after autologous stem cell transplant in patients with newly diagnosed multiple myeloma: results of the Spanish GEM2014MAIN trial","volume":"138","author":"Rosinol","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101413_bb0480","author":"Inc MG"},{"issue":"2","key":"10.1016\/j.blre.2026.101413_bb0485","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2026.101413_bb0490","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable residual disease\u2013guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2026.101413_bb0495","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood.2024026230","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial","volume":"146","author":"Perrot","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2026.101413_bb0500","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-200210","article-title":"MRD-guided sequential therapy for deep response in newly diagnosed multiple myeloma (NDMM)- master-2 trial","volume":"144","author":"Dhakal","year":"2024","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T21:09:27Z","timestamp":1787951367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":99,"alternative-id":["S0268960X26000524"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101413","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MRD in multiple myeloma: Moving from \u201cminimal\u201d to \u201cmeasurable\u201d","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101413","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101413"}}